Atara Biotherapeutics Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Operating activities
Net loss	$ (92,326)	$ (53,082)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	15,013	11,003
Amortization of investment premiums and discounts	(756)	459
Depreciation and amortization expense	1,064	428
Non-cash interest expense	125	0
Asset retirement obligation accretion expense	16	0
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(1,961)	(725)
Other assets	(102)	(74)
Accounts payable	(207)	253
Accrued compensation	(388)	(483)
Accrued research and development expenses	2,655	(337)
Other current liabilities	2,545	160
Long-term liabilities	66	63
Net cash used in operating activities	(74,256)	(42,335)
Investing activities
Purchases of short-term investments	(357,647)	(112,395)
Maturities of short-term investments	51,984	115,349
Sales of short-term investments	79,126	51,711
Purchases of property and equipment	(27,257)	(4,341)
Net cash (used in) provided by investing activities	(253,794)	50,324
Financing activities
Proceeds from sale of common stock in underwritten offerings, net	293,290	0
Proceeds from issuance of common stock from "at-the-market" facility, net	47,586	9,326
Proceeds from employee stock awards	14,857	495
Taxes paid related to net share settlement of restricted stock units	(3,431)	(341)
Principal payments on capital lease obligations	(272)	0
Net cash provided by financing activities	352,030	9,480
Increase in cash, cash equivalents and restricted cash	23,980	17,469
Cash, cash equivalents and restricted cash at beginning of period	80,617	48,162
Cash, cash equivalents and restricted cash at end of period	104,597	65,631
Non-cash investing and financing activities
Property and equipment purchases included in accounts payable and other accrued liabilities	5,078	2,502
Facility lease financing obligations	441	10,870
Property & equipment acquired under capital leases	191	0
Asset retirement cost	88	0
Interest capitalized during construction period for build-to-suit lease transaction	77	95
Supplemental cash flow disclosure
Cash paid for interest	$ 67	$ 0